Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer.

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test.Please watch the video at Investors.com - The Cell Therapy Market Is ...

But when her lung collapsed again years later, she had Medicaid coverage. Wynn was admitted to the hospital, received ...

The analyst from Canaccord Genuity noted Guardant Health (NASDAQ:GH)'s extensive experience in blood-based cancer detection ...

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...